Lundbeck and Otsuka further expand their alliance and enter into collaboration
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist currently in development for the treatment of Alzheimer's disease.
AstraZeneca settles litigation over CRESTOR patent
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into a settlement agreement in its US patent infringement litigation against Watson Laboratories, Inc., Actavis, Inc. (formerly known as Watson Pharmaceuticals, Inc.), and EGIS Pharmaceuticals regarding Watson's proposed rosuvastatin zinc product.
Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
- Details
- Category: Novartis
New data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya® (fingolimod), the first oral disease modifying therapy approved to treat relapsing forms of multiple sclerosis (MS), significantly and consistently reduced the rate of brain volume loss.
Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF).
$500,000 endowment gift from the GlaxoSmithKline Foundation
- Details
- Category: GlaxoSmithKline
The Children's Hospital of Philadelphia is proud to announce a $500,000 gift from the GlaxoSmithKline (GSK) Foundation. The donation will greatly enhance the GlaxoSmithKline Hope for Families Fund, an endowment fund which was established in 2008 with a $1 million gift from The GlaxoSmithKline Foundation and GlaxoSmithKline, and matched by The Children's Hospital of Philadelphia.
AstraZeneca to establish strategic R&D centres
- Details
- Category: AstraZeneca
AstraZeneca has announced plans to invest in strategic research and development centres in the UK, the US and Sweden to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation.
Merck announces collaboration with nordic Bioscience for Sprifermin
- Details
- Category: Merck Group
Merck today announced a strategic alliance with Nordic Bioscience Clinical Development A/S on Merck's investigational drug sprifermin (recombinant human FGF-18) in osteoarthritis (OA) of the knee. This agreement underscores Merck's commitment to osteoarthritis research and development.
More Pharma News ...
- Shire acquires Premacure AB
- American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education
- Bayer to collaborate with the Children's Hospital & Research Center Oakland to fight rare blood diseases
- United States Patent & Trademark Office grants Pfizer reissue patent for Celebrex®
- Australia Federal Court holds CRESTOR patents invalid
- Bayer: continuing growth momentum
- Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa